Gynecologic Cancer
Conference Coverage
Ovarian Cancer: Another Promising Target for Liquid Biopsy
A test under development “looks very sensitive for detecting ovarian cancer early.”
Conference Coverage
Repeat MCED Testing May ID Early-Stage and Unscreened Cancers
Eight of 26 patients with cancer signals detected through MCED had cancer.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.
Conference Coverage
Money, Ethnicity, and Access Linked to Cervical Cancer Disparities
An online analytic tool provides visual evidence of the geographic and demographic disparities in incident and recurrent/metastatic cervical...
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...
Feature
Women’s Cancers: Clinicians Research, Advise on Sexual Dysfunction
New research highlights the importance of discussing risks of sexual dysfunction in patients with women’s cancers.
Latest News
New Data: Black Women More Likely to Die From Common Endometrial Cancer Subtype
Black patients had more than two times the risk of dying from their cancer and they are underrepresented in clinical trials.
Latest News
Ovarian Cancer Red Flags: What to Know to Quicken Diagnoses
Nonspecific symptoms of ovarian cancer are not reported by patients or are not investigated by primary care physicians.
From the Journals
Few Childhood Cancer Survivors Get Recommended Screenings
‘As many as four out of five of these survivors will develop a serious or life-threatening late effect of their cancer therapy by age 45,’ the...
Conference Coverage
Minimally Invasive Cytoreductive Approach Comparable to Open Surgery for Ovarian Cancer
There were no differences in survival for patients with complete gross resections who underwent interval debulking via laparoscopy/robotics or...
Conference Coverage
Therapeutic HPV16 vaccine clears virus in most patients with CIN
An experimental vaccine delivered by electroporation cleared virus in 78% of women with CIN2/3 by 6 months.